Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.

SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.

The ophthalmic treatment developer has now raised almost $36m in total, with CR-CP Life Science Fund having led a $25m round.

Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

Softbank Investment Advisors and existing investor GV contributed to a series C round boosting the drug discovery platform developer's overall funding to over $640m.

The Keio University-backed digital medicine developer has secured $19.3m from a consortium including several Japanese corporations.

Dai-ichi Life, Itochu Technology Ventures, Koshidaka and Toyoshima CVC were among the investors that backed the medical therapy booking platform’s $19.3m round.